麝香保心丸配合美托洛尔治疗冠心病心绞痛的疗效观察

Observation on Curative Effect of Shexiang Baoxin Pill Combined with Metoprolol in Treating Angina Pectoris of Coronary Heart Disease

目的探讨麝香保心丸配合美托洛尔治疗冠心病心绞痛的疗效.方法选择2022年5月—2022年12月我院收治的100例冠心病心绞痛患者为研究对象,按随机数字表法分为对照组和观察组,各50例.对照组采用美托洛尔治疗,观察组采用麝香保心丸联合美托洛尔治疗,两组均连续治疗12周.比较两组患者的临床疗效、心绞痛发作情况、心肌缺血、心功能及不良反应发生情况.结果观察组的治疗有效率为96.00%,高于对照组的84.00%,差异有统计学意义(P<0.05).治疗12周后,观察组心绞痛发作次数为(2.25±0.33)次,少于对照组的(5.48±1.13)次;心绞痛持续时间为(2.38±0.51)min,短于对照组的(4.26±0.69)min;肌酸激酶同工酶、乳酸脱氢酶活性、缺血修饰白蛋白水平分别为(1.17±0.22)μg/L、(34.24±10.23)U/L、(22.28±4.67)U/mL,均低于对照组的(1.41±0.20)μg/L、(40.06±10.98)U/L、(28.68±7.65)U/mL,组间差异有统计学意义(P<0.05).治疗12周后,心输出量、左室射血分数分别为(5.86±0.75)L/min、(58.94±5.16)%,均高于对照组的(4.92±0.67)L/min、(53.78±5.02)%;左心室收缩末期内径,左心室舒张末期内径分别为(33.42±2.42)mm、(52.14±2.62)mm,均短于对照组的(39.74±2.65)mm、(59.01±2.41)mm,组间差异有统计学意义(P<0.05).两组不良反应发生率比较,差异无统计学意义(P>0.05).结论对冠心病心绞痛患者使用麝香保心丸与美托洛尔联合治疗效果更佳,不仅可以降低患者心绞痛发生频率,缩短其持续时间,还可改善患者心肌缺血及心功能,安全可靠.

Objective To investigate the curative effect of Shexiang Baoxin pill combined with metoprolol on angina pectoris of coronary heart disease.Methods 100 patients with angina pectoris of coronary heart disease treated in our hospital from May 2022 to December 2022 were selected as the study objects,and were divided into control group and observation group with 50 cases each according to random number table method.The control group was treated with metoprolol,and the observation group was treated with Shexiang Baoxin pill combined with metoprolol.Both groups were treated continuously for 12 weeks.The clinical efficacy,angina pectoris attack,myocardial ischemia,cardiac function and adverse reactions were compared between the two groups.Results The effective rate of observation group was 96.00%,which was higher than 84.00%of the control group,and the difference was statistically significant(P<0.05).12 weeks after treatment,the incidence of angina pectoris in the observation group was(2.25±0.33)times,less than(5.48±1.13)times in the control group;the duration of angina pectoris was(2.38±0.51)min,which was shorter than(4.26±0.69)min of the control group;creatine kinase isoenzyme,lactate dehydrogenase activity and ischa-modified albumin were(1.17±0.22)μg/L,(34.24±10.23)U/L and(22.28±4.67)U/mL,respectively,they were lower than(1.41±0.20)μg/L,(40.06±10.98)U/L and(28.68±7.65)U/mL in the control group,and the differences between groups were statistically significant(P<0.05).12 weeks after treatment,cardiac output and left ventricular ejection fraction were(5.86±0.75)L/min and(58.94±5.16)%,respectively,higher than(4.92±0.67)L/min and(53.78±5.02)%of the control group;left ventricular end-systolic diameter and left ventricular end-diastolic diameter were(33.42±2.42)mm and(52.14±2.62)mm,respectively,which were shorter than(39.74±2.65)mm and(59.01±2.41)mm of the control group,and the differences between groups were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of Shexiang Baoxin Pill and Metoprolol has a better therapeutic effect on patients with coronary heart disease and angina pectoris.It can not only reduce the frequency of angina and shorten its duration,but also improve myocardial ischemia and heart function,making it safe and reliable.